Ocular Therapeutix prices $475 million common stock offering

Ocular Therapeutix (OCUL) has priced an underwritten offering of 37.9 million shares at $12.53 per share, raising approximately $475 million in gross proceeds, following a significant stock surge over the past six months. This crucial capital raise, occurring amidst negative EBITDA, is primarily designated to fund the company's advanced clinical pipeline, including the open-label extension study and planned Phase 3 trials for AXPAXLI in wet age-related macular degeneration and non-proliferative diabetic retinopathy, along with infrastructure investments. The offering supports key development initiatives for AXPAXLI, which has garnered positive analyst coverage and is progressing towards topline Phase 3 results in Q1 2026.

Analysis

Ocular Therapeutix (OCUL) has successfully priced a significant secondary offering, raising approximately $475 million in gross proceeds by issuing 37.9 million shares at $12.53 each. This capital infusion is a critical de-risking event, executed following a more than 70% surge in its stock price over the past six months. The proceeds are earmarked to fund pivotal late-stage development of its lead asset, AXPAXLI, including an open-label extension study and planned Phase 3 trials for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy. This financing is essential given the company's negative EBITDA of -$237.32 million, providing a clear financial runway through key clinical milestones. The outlook for AXPAXLI is supported by positive operational momentum, including a high retention rate of over 95% in its SOL-1 trial, with topline results anticipated in Q1 2026, and a Special Protocol Assessment agreement with the FDA. This progress has attracted favorable analyst coverage, with Chardan initiating a Buy rating with a $21 price target and TD Cowen reiterating its Buy rating with a $14 target, signaling confidence in the upcoming trial data.

Key Decisions for Investors

• Investors should consider that the $475 million capital raise significantly strengthens Ocular Therapeutix's balance sheet and provides a clear funding runway through the pivotal AXPAXLI Phase 3 data readout in Q1 2026, reducing near-term financing risk.
• Given the stock's 70% appreciation in the last six months and the dilutive impact of the offering, investors should weigh the current $2.16 billion valuation against the binary risk of the upcoming clinical trial results, which remain the primary driver of future value.
• Monitor progress on the AXPAXLI clinical trials closely, as any updates on patient retention, safety, or timelines ahead of the Q1 2026 data release will be key catalysts for the stock.